相关实验视频
Updated: Jan 30, 2026

11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.8K
经手术使用GLP-1受体激动剂与ACDF后的修订和并发症减少有关:与倾向匹配的分析
Matthew T Kim1, Seungjun Lee2, Graham S Goh1
1Department of Orthopaedic Surgery, Boston University Medical Center, Boston, MA, USA.
Global spine journal
|January 29, 2026
概括
在接受前椎切除和融合 (ACDF) 的2型糖尿病患者中使用类似葡萄糖-1受体激活剂 (GLP-1RAs) 与较少的并发症有关. 这包括较低的伪,修复手术和消化不良率,以及减少医疗保健利用率.
科学领域:
- 脊柱外科手术 脊柱外科手术
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 用于治疗肥胖和2型糖尿病 (T2DM).
- GLP-1RAs具有抗炎和骨质性质,可能会影响脊髓融合结果.
- 前椎切除和融合 (ACDF) 是用于椎脊柱疾病的常见手术程序.
研究的目的:
- 调查手术前GLP-1RA使用与经过ACDF的T2DM患者的术后结果之间的关联.
- 评估GLP-1RA治疗对ACDF后并发症,资源利用率和修订率的影响.
- 为了确定GLP-1RA使用是否会影响ACDF后的伪关节炎和食障碍的风险.
主要方法:
- 使用TriNetX全球网络进行的回顾性队列研究.
- 包括接受单一或多级ACDF的T2DM患者.
- 倾向性得分与混变量的控制匹配.
- 基于手术前和后6个月内处方的GLP-1RA使用者的定义.
- 评估结果,包括并发症,修订和90天,6个月和1年的医疗保健利用情况.
主要成果:
- 在90天和6个月的单一水平ACDF后,GLP-1RA的使用与修订率显著降低有关.
- 对单级和多级ACDF在所有时间点中观察到的伪风险降低.
- 在GLP-1RA使用者中,单级ACDF后,食障碍的发病率较低.
- 减少了GLP-1RA使用者的医疗保健利用率,包括更少的再入院和急诊室访问.
- 多变量分析证实了GLP-1RA的使用,作为减少1年伪的独立预测因子.
结论:
- 在T2DM患者中,经外科手术的GLP-1RA治疗与ACDF后的良好结果有关.
- GLP-1RA的使用与伪,修复手术和消化不良的发病率降低相关.
- 用GLP-1RAs治疗似乎可以减少医疗资源利用率,而不会增加不良事件.
- 这些发现表明GLP-1RAs在改善ACDF手术结果方面具有潜在的益处.
相关概念视频
Glucagon-like Receptor Agonists
953
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
953
Drug-Receptor Interaction: Agonist
4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
971
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
971
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
505
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
505
Sign Test for Matched Pairs
405
The sign test for matched pairs offers a robust method for comparing two paired samples, often for the effects of an intervention in one of them. This method is very useful in situations where the underlying distribution of the data is unknown. The test compares two related samples—often pre- and post-treatment measurements on the same subjects—to determine if there are significant differences in their median values.
To conduct the sign test, we first calculate the differences in...
To conduct the sign test, we first calculate the differences in...
405
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
618
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
618

